Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates.

Read more at globenewswire.com